Dubai: The 31st edition of the Dubai International Pharmaceuticals and Technologies Conference and Exhibition - DUPHAT 2026 concluded successfully today at Dubai World Trade Centre, marking three days of high-level discussions, scientific exchange, and industry engagement.
According to Emirates News Agency, the event recorded approximately AED10.3 billion in direct and indirect trade deals over the three days, further highlighting its role as a leading platform for advancing the pharmaceutical sector and fostering business opportunities. The event brought together leading experts, healthcare professionals, researchers, and decision-makers from across the pharmaceutical and healthcare sectors to explore the future of pharmacy and the evolving role of pharmacists amid rapid advances in artificial intelligence, precision medicine, and biotechnology.
Discussions also focused on medication safety, pharmacy education, research, and stronger collaboration across the healthcare ecosystem, with an emphasis on transforming scientific knowledge and technological innovation into practical solutions that improve patient outcomes and strengthen healthcare delivery.
Amb. Prof. Abdulsalam AlMadani, Chairman of DUPHAT and DUPHAT International Scientific Council (DISC), Roving Ambassador of the Parliamentary Assembly of the Mediterranean (PAM) for the GCC Region, stated that DUPHAT 2026 once again demonstrated the strength and growth potential of the pharmaceutical sector. He emphasized the significant trade deals recorded during the edition, which reflect growing confidence in the pharmaceutical and healthcare sectors, reinforcing Dubai's position as a global hub for business, innovation, and scientific collaboration.
Dr. Farida Alkhaja, Chair of the Scientific Committee of DUPHAT 2026, highlighted the UAE's strong combination of scientific expertise, technology, talent, and experience. She emphasized that the success of a congress should not be measured only by the knowledge exchanged but by its ability to turn dialogue into action and inspire a continued commitment to putting patients first, advancing research, using technology responsibly, and preparing the next generation of pharmacists.
DUPHAT 2026 concluded with a series of key recommendations focused on strengthening the role of pharmacists in the future of healthcare. This includes a call to move from AI adoption to responsible AI leadership, making patient outcomes the ultimate measure of healthcare innovation, and integrating medication safety as a core element of healthcare innovation. The conference underscored that innovation should never outpace safety.
Another key recommendation was to prepare pharmacists for precision and personalized healthcare, ensuring they are equipped with knowledge in pharmacogenomics, precision medicine, and emerging biotechnology. DUPHAT 2026 also called for pharmacy education to be redesigned around the needs of the future, emphasizing scientific, clinical, leadership, and digital competence.
The conference highlighted the importance of stronger collaboration across the healthcare ecosystem, bringing together various stakeholders to translate scientific progress and technological innovation into sustainable improvements in healthcare.
As DUPHAT 2026 concluded, it reaffirmed that every step forward in pharmacy should contribute to safer patients, healthier communities, and a better future for healthcare. The Scientific Committee concluded the edition by thanking participants and looking ahead to DUPHAT 2027 for continued collaboration to advance the future of pharmacy and pharmaceutical technologies.
The Dubai International Pharmaceuticals and Technologies Conference and Exhibition - DUPHAT 2026 is officially supported by Emirates Drug Establishment and Dubai Health Authority and is organized by INDEX Conferences and Exhibitions org., a member of INDEX Holding. Supporting partners of DUPHAT include the American Pharmacists Association, European Society of Clinical Pharmacy (ESCP), European Federation for Pharmaceutical Sciences EUFEPS, Accreditation Council for Pharmacy Education (ACPE), European Society of Oncology Pharmacy ESOP, International Pharmaceutical Federation (FIP), and International Association of Therapeutic Drug Monitoring and Clinical Toxicology IATDMCT.